Answers are grounded in this paper and cite their sources.
Case reports highlight the need for documenting antitoxin decisions in infant botulism, suggesting guidelines for treatment.
In infant botulism, use of equine‐derived botulinum antitoxin before BIG‐IV may be clinically justified when the infant‐specific product is delayed. Future case reports should document the treatment decision pathway, antitoxin timing, risk–benefit justification, guardian counseling, adverse‐event monitoring, and relapse‐prevention rationale to make such emergency decisions reproducible.
No takes yet. Share an insight, caveat, or question.
Awan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: